{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:25:41Z","timestamp":1787502341307,"version":"build-2736575974"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["565038"],"award-info":[{"award-number":["565038"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immunosuppressant (IS) therapeutic drug monitoring (TDM) relies on measuring mostly pharmacologically inactive erythrocyte-bound and\/or plasma protein\u2013bound drug levels. Variations in hematocrit and plasma protein levels complicate interpretation of blood calcineurin inhibitor (CNI) and inhibitors of the\u00a0molecular target of rapamycin (mTORi) concentrations. Variable binding of mycophenolic acid (MPA) to albumin similarly complicates its TDM in plasma. A different matrix may improve IS concentration\u2013response relationships and better reflect exposures at sites of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review explores the evidence for IS TDM using peripheral blood mononuclear cell (PBMC), graft tissue, and total or unbound plasma concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Tandem mass spectrometry provides the sensitivity for assessing these matrices. But several challenges must be addressed, including minimizing hemolysis during blood collection, preventing IS efflux during PBMC preparation, and determining the need for further purification of the PBMC fraction. Assessing and reducing nonspecific binding during separation of unbound IS are also necessary, especially for lipophilic CNIs\/mTORi. Although TDM using PBMC or unbound plasma concentrations may not be feasible due to increased costs, plasma CNI\/mTORi levels may be more easily integrated into routine TDM. However, no validated TDM targets currently exist, and published models to adjust blood CNI\/mTORi concentrations for hematocrit or to predict PBMC, and total and unbound plasma IS concentrations have yet to be validated in terms of measured concentrations or prediction of clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Even if CNI\/mTORi measurements in novel matrices do not become routine, they may help refine pharmacokinetic\u2013pharmacodynamic relationships and improve mathematical models for TDM using whole blood. Notably, there is evidence to support measuring unbound MPA in patients with severe renal dysfunction, hypoalbuminemia, and hyperbilirubinemia, with some proposed TDM targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001282","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T21:00:19Z","timestamp":1732654819000},"page":"105-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Alternate Sampling Matrices for Therapeutic Drug Monitoring of Immunosuppressants"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0186-3073","authenticated-orcid":false,"given":"Benedetta C.","family":"Sallustio","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, SA, Australia; and"},{"name":"Discipline of Pharmacology, School of Biomedicine, The University of Adelaide, Adelaide, SA, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"101756","DOI":"10.1016\/j.bpg.2021.101756","article-title":"Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology","volume":"54\u201355","author":"Udomkarnjananun","year":"2021","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"de Jonge","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/17512433.2024.2354276","article-title":"Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions","volume":"17","author":"Ntobe-Bunkete","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.trim.2014.05.002","article-title":"Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes","volume":"31","author":"Shihab","year":"2014","journal-title":"Transpl Immunol"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","article-title":"Therapeutic drug monitoring of everolimus: a consensus report","volume":"38","author":"Shipkova","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.2042-7158.1987.tb03436.x","article-title":"Cyclosporin: measurement of fraction unbound in plasma","volume":"39","author":"Legg","year":"1987","journal-title":"J Pharm Pharmacol"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.2042-7158.1982.tb06206.x","article-title":"Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood","volume":"34","author":"Lemaire","year":"1982","journal-title":"J Pharm Pharmacol"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jcp.37.10.1167","article-title":"Distribution and concentration of cyclosporin in human blood","volume":"37","author":"Atkinson","year":"1984","journal-title":"J Clin Pathol"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0005-2736(88)90142-3","article-title":"Identification of cyclophilin as the erythrocyte ciclosporin-binding protein","volume":"938","author":"Foxwell","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00191903","article-title":"Characterization of cyclosporine A uptake in human erythrocytes","volume":"46","author":"Reichel","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00003088-200241090-00001","article-title":"Distribution of cyclosporin in organ transplant recipients","volume":"41","author":"Akhlaghi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.2042-7158.1994.tb03752.x","article-title":"Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes","volume":"46","author":"Nagase","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","article-title":"Factors affecting variability in distribution of tacrolimus in liver transplant recipients","volume":"57","author":"Zahir","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","article-title":"Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation","volume":"26","author":"Zahir","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","article-title":"Validation of methods to study the distribution and protein binding of tacrolimus in human blood","volume":"46","author":"Zahir","year":"2001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/clinchem\/39.6.1045","article-title":"Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours","volume":"39","author":"Wallemacq","year":"1993","journal-title":"Clin Chem"},{"key":"R20-20250108","first-page":"251","article-title":"Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid","volume":"94","author":"Iwasaki","year":"1996","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/00007890-199311000-00029","article-title":"Blood distribution of rapamycin","volume":"56","author":"Yatscoff","year":"1993","journal-title":"Transplantation"},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","article-title":"Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion","volume":"23","author":"Shaw","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/clinchem\/41.7.1011","article-title":"Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics","volume":"41","author":"Nowak","year":"1995","journal-title":"Clin Chem"},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1023\/A:1015932032609","article-title":"Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment","volume":"5","author":"Legg","year":"1988","journal-title":"Pharm Res"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00007691-199512000-00020","article-title":"Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations","volume":"17","author":"Yatscoff","year":"1995","journal-title":"Ther Drug Monit"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF01046701","article-title":"Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration","volume":"34","author":"Legg","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","article-title":"Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40262-016-0414-3","article-title":"A semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients","volume":"55","author":"van Erp","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40262-017-0603-8","article-title":"Prediction of free from total mycophenolic acid concentrations in stable renal transplant patients: a population-based approach","volume":"57","author":"Colom","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","article-title":"Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients","volume":"36","author":"de Winter","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MAJ.0b013e318095a4ae","article-title":"The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit","volume":"334","author":"Dunn","year":"2007","journal-title":"Am J Med Sci"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/lt.21622","article-title":"Liver regeneration in donors and adult recipients after living donor liver transplantation","volume":"14","author":"Haga","year":"2008","journal-title":"Liver Transpl"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02888.x","article-title":"Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients","volume":"64","author":"Antignac","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol Res"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/FTD.0000000000000780","article-title":"Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology expert panel","volume":"42","author":"Lemaitre","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"733285","DOI":"10.3389\/fphar.2021.733285","article-title":"Monitoring intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue","volume":"12","author":"Sallustio","year":"2021","journal-title":"Front Pharmacol"},{"key":"R39-20250108","first-page":"382","article-title":"Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?","volume":"107","author":"Udomkarnjananun","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/S0041-1345(01)02190-X","article-title":"Cyclosporine lymphocyte versus whole blood pharmacokinetic monitoring: correlation with histological findings","volume":"33","author":"Barbari","year":"2001","journal-title":"Transpl Proc"},{"key":"R41-20250108","first-page":"400","article-title":"Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study","volume":"4","author":"Barbari","year":"2006","journal-title":"Exp Clin Transpl"},{"key":"R42-20250108","first-page":"293","article-title":"Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation","volume":"3","author":"Barbari","year":"2005","journal-title":"Exp Clin Transpl"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/TP.0b013e31815feede","article-title":"Declining intracellular T-lymphocyte concentration of Cyclosporine A precedes acute rejection in kidney transplant recipients","volume":"85","author":"Falck","year":"2008","journal-title":"Transplantation"},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transpl Int"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.clinthera.2018.10.015","article-title":"Tacrolimus concentrations measured in excreted bile in liver transplant recipients: the STABILE study","volume":"40","author":"Rayar","year":"2018","journal-title":"Clin Ther"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/bcp.14585","article-title":"Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients","volume":"87","author":"Francke","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"e0153491","DOI":"10.1371\/journal.pone.0153491","article-title":"Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinbiochem.2021.12.002","article-title":"Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation","volume":"101","author":"Francke","year":"2022","journal-title":"Clin Biochem"},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s13318-022-00767-8","article-title":"A population pharmacokinetic model of whole-blood and intracellular tacrolimus in kidney transplant recipients","volume":"47","author":"Franken","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/FTD.0000000000000982","article-title":"Association between the intracellular tacrolimus concentration in CD3 + T lymphocytes and CD14 + monocytes and acute kidney transplant rejection","volume":"44","author":"Udomkarnjananun","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FTD.0000000000001025","article-title":"Blood, cellular, and tissular calcineurin inhibitors pharmacokinetic-pharmacodynamic relationship in heart transplant recipients: the INTRACAR study","volume":"45","author":"Coste","year":"2023","journal-title":"Ther Drug Monit"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"636048","DOI":"10.3389\/fphar.2021.636048","article-title":"Influence of the circadian timing system on tacrolimus pharmacokinetics and pharmacodynamics after kidney transplantation","volume":"12","author":"Fontova","year":"2021","journal-title":"Front Pharmacol"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clinbiochem.2014.12.018","article-title":"Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells","volume":"48","author":"Lemaitre","year":"2015","journal-title":"Clin Biochem"},{"key":"R54-20250108","doi-asserted-by":"crossref","first-page":"e0230195","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic-whole blood and intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PLoS One"},{"key":"R55-20250108","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/pharmaceutics15051481","article-title":"The effect of intracellular tacrolimus exposure on calcineurin inhibition in immediate- and extended-release tacrolimus formulations","volume":"15","author":"Fontova","year":"2023","journal-title":"Pharmaceutics"},{"key":"R56-20250108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/fcp.12412","article-title":"Tacrolimus diffusion across the peripheral mononuclear blood cell membrane: impact of drug transporters","volume":"33","author":"Tron","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"R57-20250108","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jpba.2018.01.002","article-title":"UPLC-MS\/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes","volume":"152","author":"Romano","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/bio.2015.0104","article-title":"Comparison of three isolation techniques for human peripheral blood mononuclear cells: cell recovery and viability, population composition, and cell functionality","volume":"14","author":"Grievink","year":"2016","journal-title":"Biopreserv Biobank"},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/TP.0000000000004287","article-title":"P-glycoprotein, FK-binding protein-12, and the intracellular tacrolimus concentration in T-lymphocytes and monocytes of kidney transplant recipients","volume":"107","author":"Udomkarnjananun","year":"2023","journal-title":"Transplantation"},{"key":"R60-20250108","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3390\/ijms20194710","article-title":"Immunomonitoring of tacrolimus in healthy volunteers: the first step from PK- to PD-based therapeutic drug monitoring?","volume":"20","author":"In 't Veld","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R61-20250108","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00007890-200007270-00017","article-title":"Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations","volume":"70","author":"Kung","year":"2000","journal-title":"Transplantation"},{"key":"R62-20250108","doi-asserted-by":"crossref","first-page":"e1319","DOI":"10.1097\/TXD.0000000000001319","article-title":"Immune subsets from ficoll density gradient separation in kidney transplant recipients","volume":"8","author":"Udomkarnjananun","year":"2022","journal-title":"Transpl Direct"},{"key":"R64-20250108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/FPC.0b013e3282f7046f","article-title":"Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients","volume":"18","author":"Crettol","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R63-20250108","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R65-20250108","first-page":"143","article-title":"Current methods of haemolysis detection and reporting as a source of risk to patient safety: a narrative review","volume":"37","author":"McCaughey","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"R66-20250108","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.transproceed.2007.04.008","article-title":"An assay for the determination of sirolimus levels in the lymphocyte of transplant patients","volume":"39","author":"Masri","year":"2007","journal-title":"Transpl Proc"},{"key":"R67-20250108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jpba.2012.03.042","article-title":"Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry","volume":"66","author":"Roullet-Renoleau","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"R68-20250108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/FTD.0000000000000185","article-title":"Closer to the site of action: everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations","volume":"37","author":"Robertsen","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R69-20250108","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s40262-018-0646-5","article-title":"A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators","volume":"57","author":"Robertsen","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R70-20250108","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.clinbiochem.2013.09.009","article-title":"Mycophenolic acid quantification in human peripheral blood mononuclear cells using liquid chromatography-tandem mass spectrometry","volume":"46","author":"Nguyen Thi","year":"2013","journal-title":"Clin Biochem"},{"key":"R71-20250108","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1111\/bcp.13704","article-title":"Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients","volume":"84","author":"Md Dom","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R72-20250108","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hep.1840150619","article-title":"Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection","volume":"15","author":"Sandborn","year":"1992","journal-title":"Hepatology"},{"key":"R73-20250108","first-page":"70","article-title":"Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue","volume":"21","author":"Sandborn","year":"1995","journal-title":"Hepatology"},{"key":"R74-20250108","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/FTD.0b013e31805c73f1","article-title":"Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection","volume":"29","author":"Capron","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R75-20250108","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1111\/bcp.14806","article-title":"Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5\/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients","volume":"87","author":"Sallustio","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R76-20250108","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.3390\/ijms21082976","article-title":"Donor CYP3A5 gene polymorphism alone cannot predict tacrolimus intrarenal concentration in renal transplant recipients","volume":"21","author":"Zhang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R77-20250108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FTD.0000000000001135","article-title":"Determining plasma tacrolimus concentrations using high-performance LC-MS\/MS in renal transplant recipients","volume":"46","author":"Alonge","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R78-20250108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/FTD.0000000000000351","article-title":"Development of a simple and rapid method to measure the free fraction of tacrolimus in plasma using ultrafiltration and LC-MS\/MS","volume":"38","author":"Stienstra","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R79-20250108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0b013e3182708edf","article-title":"Pharmacokinetics of tacrolimus during pregnancy","volume":"34","author":"Zheng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R80-20250108","doi-asserted-by":"crossref","first-page":"123709","DOI":"10.1016\/j.jchromb.2023.123709","article-title":"Expeditious quantification of plasma tacrolimus with liquid chromatography tandem mass spectrometry in solid organ transplantation","volume":"1222","author":"Zijp","year":"2023","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R81-20250108","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/FTD.0000000000000656","article-title":"Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?","volume":"41","author":"Hu","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R82-20250108","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.transproceed.2004.04.097","article-title":"Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients","volume":"36","author":"Minematsu","year":"2004","journal-title":"Transpl Proc"},{"key":"R83-20250108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00467-018-4117-x","article-title":"The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients","volume":"34","author":"Schijvens","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R84-20250108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"St\u00f8rset","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R85-20250108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"Storset","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R86-20250108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","article-title":"Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients","volume":"45","author":"Sam","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R87-20250108","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40262-023-01259-x","article-title":"A joint pharmacokinetic model for the simultaneous description of plasma and whole blood tacrolimus concentrations in kidney and lung transplant recipients","volume":"62","author":"Koomen","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R88-20250108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.chroma.2018.03.010","article-title":"A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples","volume":"1547","author":"Bittersohl","year":"2018","journal-title":"J Chromatogr A"},{"key":"R89-20250108","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/pharmaceutics14030632","article-title":"Development and validation of the new liquid chromatography-tandem mass spectrometry method for the determination of unbound tacrolimus in the plasma ultrafiltrate of transplant recipients","volume":"14","author":"Bodnar-Broniarczyk","year":"2022","journal-title":"Pharmaceutics"},{"key":"R90-20250108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FTD.0000000000000392","article-title":"Simultaneous determination of protein-unbound cyclosporine A and mycophenolic acid in kidney transplant patients using liquid chromatography-tandem mass spectrometry","volume":"39","author":"Bittersohl","year":"2017","journal-title":"Ther Drug Monit"},{"key":"R91-20250108","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jps.2600820325","article-title":"Plasma protein binding of tacrolimus in humans","volume":"82","author":"Piekoszewski","year":"1993","journal-title":"J Pharm Sci"},{"key":"R92-20250108","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2125.2004.02235.x","article-title":"Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant","volume":"59","author":"Atcheson","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R93-20250108","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00007691-200408000-00017","article-title":"Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient","volume":"26","author":"Mudge","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R94-20250108","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.12678","article-title":"Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis","volume":"80","author":"Abd Rahman","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R95-20250108","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.08.009","article-title":"Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation","volume":"78","author":"Jacobson","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R96-20250108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbmt.2009.11.010","article-title":"Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network","volume":"16","author":"Jacobson","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"R97-20250108","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbmt.2018.01.040","article-title":"Pharmacokinetic and pharmacodynamic markers of mycophenolic acid associated with effective prophylaxis for acute graft-versus-host disease and neutrophil engraftment in cord blood transplant patients","volume":"24","author":"Yoshimura","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"R98-20250108","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00007691-200406000-00011","article-title":"Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia","volume":"26","author":"Atcheson","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R99-20250108","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FTD.0b013e31820c0a96","article-title":"How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation","volume":"33","author":"van Gelder","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R100-20250108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/11312600-000000000-00000","article-title":"Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients","volume":"48","author":"van Hest","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R101-20250108","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/FTD.0b013e318074d979","article-title":"Prediction of unbound mycophenolic acid concentrations in patients after hematopoietic cell transplantation","volume":"29","author":"Huang","year":"2007","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:01:33Z","timestamp":1736330493000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001282","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"2024-08-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}